Abstract: Disclosed is a plasmid standard for use in fluorescent quantitative PCR assays. More specifically, the present invention provides a plasmid standard as well as amplification primers and detection probes thereof for use in the detection of gene mutation and expression amount.

Abstract: The present invention relates to a method and assay kit for BRAF gene mutations which relates to the effect of molecule-targeting anti-tumor drug. Particularly, the present invention relates to a fluorescent quantitative PCR method and kit for detecting mutations at hotspots of BRAF gene, together with the use thereof. The present invention detects the mutations at specific sites of BRAF gene, and can predict the therapeutic efficacy of anti-EGFR tyrosine kinase inhibitors, an anti-tumor drug. Therefore, the present invention can provide a guidance to individualized treatments for cancer patients.

Abstract: The present invention relates to an assay kit for quantitatively detecting k-ras gene mutations. Particularly, the present invention relates to detection method and a detection kit for K-ras gene mutations, which relates to the therapeutic efficacy of targeted molecular anti-cancer drugs. More particularly, the present invention relates to a fluorescent quantitative PCR method and kit for detecting mutations at hotspots of K-ras gene, together with the use thereof. The present invention detects the mutations at specific sites of K-ras gene, and can predict the therapeutic efficacy of anti-EGFR tyrosine kinase inhibitors. Therefore, it can provide a guidance to individualized treatments for cancer patients.

Abstract: The present invention relates to a detection method and a detection kit for EGFR gene mutations, which relates to the therapeutic efficacy of molecular-targeted anti-cancer drugs. Particularly, the present invention relates to a fluorescent quantitative PCR method and kit for detecting mutations at hotspots of EGFR gene, together with the use thereof. The present invention detects the mutations at specific sites of EGFR gene, and can predict the therapeutic efficacy of EGFR tyrosine kinase inhibitors. Therefore, it can provide a guidance to individualize treatments for cancer patients.

Abstract: The present invention is directed to methods for comparatively detecting the level of human Porcupine (PPN)/MG61, a family member of membrane-bound O-acyltransferases, which is the human homologue of the Drosophila polarity gene Porcupine (Porc), and use thereof.

Abstract: The present invention relates to a kit for assaying the activity of the human arylsulphatase or its isozymes, including 4-MUS and 4-MU. The kit can be used for initial screening, therapeutic effect monitoring and recurrence inspecting of human cancers.

Abstract: The present invention is directed to methods for comparatively detecting the level of human Porcupine (PPN)/MG61, a family member of membrane-bound O-acyltransferases, which is the human homologue of the Drosophila polarity gene Porcupine (Porc), and use thereof.